J. Goldman & Co’s BioCryst Pharmaceuticals BCRX Stock Holding History

J. Goldman & Co’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-67,306	Closed	-$1.09M	–	359
2022 Q1	$1.09M	Buy	+67,306	New	+$1.08M	0.05%	249
2020 Q4	–	Sell	-118,125	Closed	-$406K	–	376
2020 Q3	$406K	Sell	118,125 -241,819	-67%	-$1.04M	0.03%	262
2020 Q2	$1.72M	Buy	+359,944	New	+$1.44M	0.11%	175

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

J. Goldman & Co's BCRX Position: Q2 2022 in Review

J. Goldman & Co sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2022, closing a stake of 67,306 shares — an estimated $1.09M sold.

J. Goldman & Co first reported a position in BCRX in Q2 2020 and held it in 3 quarters. The position peaked at $1.72M in Q2 2020. 221 funds tracked by Wall St. Rank hold BCRX as of Q2 2022.

J. Goldman & Co reported no remaining BioCryst Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
J. Goldman & Co sold 67,306 BioCryst Pharmaceuticals shares in Q2 2022, an estimated $1.09M.
J. Goldman & Co first reported a position in BioCryst Pharmaceuticals in Q2 2020 and held it in 3 quarters.
J. Goldman & Co's BioCryst Pharmaceuticals position peaked at $1.72M in Q2 2020.
221 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2022.

Based on J. Goldman & Co's 13F filing for Q2 2022, filed 15 Aug 2022.